Treatment options for C3 glomerulopathy

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 2, 2013, Pages 231-237

  Nester, Carla M ^a,c   Smith, Richard J ^a,b,c  

^a Departments of Pediatrics and Internal Medicine   (United States)

^b Iowa Institute of Human Genetics   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Alternate pathway of complement; C3 glomerulonephritis; C3 glomerulopathy; dense deposit disease; membranoproliferative glomerulonephritis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; COMPLEMENT COMPONENT C3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS;

C3 GLOMERULOPATHY; CLINICAL FEATURE; CLINICAL PROTOCOL; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; CREATININE BLOOD LEVEL; DENSE DEPOSIT DISEASE; DRUG DOSE ESCALATION; DRUG EFFICACY; ELECTRON MICROSCOPY; GLOMERULOPATHY; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT PATHWAY, ALTERNATIVE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873566027     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835da24c     Document Type: Review

References (38)

1. Fakhouri F, Fremeaux-Bacchi V, Noel L-H, et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6:494-499.
2. Servais A, Fremeaux-Bacchi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44:193-199.
3. Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (Dense Deposit Disease): an update. J Am Soc Nephrol 2005; 16:1392-1403.
4. Walker PD, Ferrario F, Joh K, Bonsib SM. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 2007; 20:605-616.
5. Lu DF, Moon M, Lanning LD, et al. Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol 2012; 27:773-781.
6. Nasr SH, Valeri AM, Appel GB, et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4:22-32.
7. Sethi S, Gamez JD, Vrana JA, et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75:952-960.
8. Smith RJH, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18:2447-2456.
9. Levy M, Halbwachs-Mecarelli L, Gubler M-C, et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986; 30:949-956.
10. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, et al. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15:787-795.
11. Licht C, Heinen S, Jozsi M, et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006; 70:42-50.
12. Martinez-Barricarte R, Heurich M, Valdes-Canedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120:3702-3712.
13. Abrera-Abeleda MA, Nishimura C, Smith JL, et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006; 43:582-589.
14. Skerka C, Lauer N, Weinberger AA, et al. Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol 2007; 44:3398-3406.
15. Laine M, Jarva H, Seitsonen S, et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 2007; 178:3831-3836.
16. Abrera-Abeleda MA, Nishimura C, Frees K, et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 2011; 22:1551-1559.
17. Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int 2012; 81:434-441.
18. Rose KL, Paixao-Cavalcante D, Fish J, et al. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 2008; 118:608-618.
19. Pickering MC, Cook HT, Warren J, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31:424-428.
20. Sethi S, Fervenza FC, Zhang Y, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011; 6:1009-1017.
21. Boyer O, Noel LH, Balzamo E, et al. Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. Am J Kidney Dis 2008; 51:671-677.
22. Vernon KA, Gale DP, de Jorge EG, et al. Recurrence of complement factor Hrelated protein 5 nephropathy in a renal transplant. Am J Transplant 2011; 11:152-155.
23. Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82:465-473.
24. Habbig S, Mihatsch MJ, Heinen S, et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75:1230-1234.
25. Athanasiou Y, Voskarides K, Gale DP, et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6:1436-1446.
26. Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376:794-801.
27. Servais A, Noel LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82:454-464.
28. Brenner BM, Cooper ME, de Zeeuw D, et al. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000; 1:328-335.
29. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with nonnephrotic proteinuria. Lancet 1999; 354:359-364.
30. Maisch NM, Pezzillo KK. HMG-CoA reductase inhibitors for the prevention of nephropathy. Ann Pharmacother 2004; 38:342-345.
31. Banks RA, May S, Wallington T. Acute renal failure in dense deposit disease: recovery after plasmapheresis. Br Med J (Clin Res Ed) 1982; 284:1874-1875.
32. Krmar RT, Holtback U, Linne T, et al. Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange. Clin Nephrol 2011; 75 (Suppl 1):4-10.
33. McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012; 12:1046-1051.
34. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012; 366:1161-1163.
35. Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7:748-756.
36. Pickering MC, Warren J, Rose KL, et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA 2006; 103:9649-9654.
37. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012; 366:1163-1165.
38. Fakhouri F, de Jorge EG, Brune F, et al. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 2010; 78:279-286.